Degarelix

July 20, 2023

Degarelix, also known as Degarelix acetate and FE-200486, a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. Degarelix is specifically indicated for the treatment of advanced prostate cancer.
Degarelix is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen. The recommended initial dose of the drug is 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL. The recommended maintenance dose of Degarelix is 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, every 28 days. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.


Status:In Mass Production
Unit:5mg,10mg,1g/customized
Capacity: 1kg/month

Request a Quick Quote

Raw Degarelix powder (214766-78-6) video

Degarelix Description

Degarelix, also known as Degarelix acetate and FE-200486,  a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR) antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone. Degarelix is specifically indicated for the treatment of advanced prostate cancer.

Degarelix is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen. The recommended initial dose of the drug is 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL. The recommended maintenance dose of Degarelix is 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, every 28 days. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Degarelix Specifications

Product NameDegarelix
Chemical NameDegarelix acetate; FE-200486; UNII-SX0XJI3A11; SX0XJI3A11; CS-5350; Z-3147; CHEMBL415606; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2;
Brand NameFirmagon
Drug ClassAntineoplastic Agents
CAS Number214766-78-6
InChIKeyMEUCPCLKGZSHTA-XYAYPHGZSA-N
Molecular FormulaC82H103ClN18O16
Molecular Weight1632.28
Monoisotopic Mass1630.75 g/mol g·mol−1
Melting Point N/A
Freezing PointN/A
Biological Half-Life23~61 days
ColorWhite to off-white solid powder
Solubility H2O: ≥ 500 mg/mL
Storage Temperature -20°C
ApplicationUsed to treat patients with advanced prostate cancer

 


Contact Us

Polypeptide Peptide dosage calculator